This pragmatic trial addresses the long-standing hypothesis that the administration of high doses of a narrow-spectrum antibiotic ( penicillin V ) in patients with non-severe pneumonia attended in the community is not less effective than high doses of amoxicillin ( treatment currently recommended ) in patients under the age of 65years .
